References
- 1. Edwards JL, Vicent AM, Cheng HT et al. Diabetic neuropathy: mechanism to management. Pharmacol Ther 2008; 120: 1-34.10.1016/j.pharmthera.2008.05.005
- 2. Kempler P. Cardiac autonomic neuropathy: Is it a cardiovascular risk factor in type 2 diabetes? In: Hâncu N [Ed]. Cardiovascular Risk in Type 2 Diabetes Mellitus: assessment and control, Springer-Verlag, Berlin Heidelberg 2003:181-192.10.1007/978-3-642-59352-9_16
- 3. DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-423.10.1007/s001250050924
- 4. Pop-Busui R. What do we know and we do not know about cardiovascular autonomic neuropathy. J Cardiovasc Transl Res 2012; 5: 463-478.10.1007/s12265-012-9367-6
- 5. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.10.2337/diacare.26.5.1553
- 6. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-397.10.1161/CIRCULATIONAHA.106.634949
- 7. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences and treatment. J Clin Endocrinol Metab 2005; 90: 5896-5903.10.1210/jc.2005-0754
- 8. Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-1270.10.1016/S0140-6736(05)74815-7
- 9. Rett K. Diabetes Therapy on the Move: Is glucocentric view outdated? In: Rett K [Ed]. Better chances for nerves and vessels, Georg Thieme Verlag KG Stuttgart 2011:1-8.
- 10. Vlad I, Popa AR. Epidemiology of diabetes mellitus: a current review. Rom J Diabetes Nutr Metab Dis. 2012; 19: 433-44010.2478/v10255-012-0050-0
- 11. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157-177.10.2337/diacare.16.1.1578123057
- 12. Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol 2015;11:220-22610.3988/jcn.2015.11.3.220450737526174784
- 13. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular diseas: physiological basis and prognostic implications. J Am Coll Cardiol 2008; 51:1725-1733.10.1016/j.jacc.2008.01.03818452777
- 14. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986; 9: 648-665.10.2337/diacare.9.6.6483100258
- 15. Pop-Busui R, Evans GW, Gerstein HC et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care 2010; 33:1578-1584.10.2337/dc10-0125289036220215456
- 16. Fedorowski A, Stavenow L, Hedblad B et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals. Eur Heart J 2010; 31: 85-91.10.1093/eurheartj/ehp329280091919696189
- 17. Mancia M, Grassi G. Orthostatic hypotension and cardiovascular risk: defining the epidemiological and prognostic relevance. Eur Heart J 2010; 31: 12-14.10.1093/eurheartj/ehp38919734166
- 18. Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 2010; 12: 261-265.10.1093/europace/eup34419887457
- 19. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285:916-918.10.1136/bmj.285.6346.91615000186811067
- 20. Tesfaye S, Boulton AJ, Dyck PJ et al. Diabetic Neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.10.2337/dc10-1303294517620876709
- 21. Ewing DJ, Martyn CN, Young RJ et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8:491-498.10.2337/diacare.8.5.4914053936
- 22. American Academy of Neurology. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 46:873-880.
- 23. Spallone V, Morganti R, Fedele T et al. Reappraisal of the diagnostic role of orthostatic hypotension in diabetes. Clin Auton Res 2009; 19: 58-64.10.1007/s10286-009-0517-019199088
- 24. Pafili K, Trypsianis G, Papzoglou D, Maltezos E, Papanas N. Simplified diagnosis of cardiovascular autonomic neuropathy in type 2 diabetes using Ewing s battery. Rev Diabet Stud. 2015;12(1-2):213-21910.1900/RDS.2015.12.213539799126676669
- 25. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope. Diabet Med 2011; 28: 643-651.10.1111/j.1464-5491.2010.03184.x312370521569084
- 26. Jermendy G, Kempler P, Keresztes K et al. The clinical features and diagnosis of autonomic neuropathy. In: Kempler P, Varkonyi T[Eds]. Neuropathies: A Global Clinical Guide, Zafir Press, Budapest 2012: 69-130.
- 27. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014;5(1):17-39.10.4239/wjd.v5.i1.17393242524567799
- 28. La Rovere M, Maestri R, Pinna G. Baroreflex sensitivity assessment: latest advances and strategies. Eur Cardiol 2011;7(2):89-92.10.15420/ecr.2011.7.2.89
- 29. Kempler P, Varadi A, Szalay F et al. Autonomic neuropathy and corrected QT interval prolongation. There is a relationship. Diabetes Care 1994; 17: 454-456.10.2337/diacare.17.5.4548062618
- 30. Schneider CA, Baer FM, Erdmann E. QT-dispersion - analysis and prognostic implications. Dtsch Med Wochenschr 1999; 124:396-402.10.1055/s-2007-102432410226648
- 31. Ziegler D, Weise F, Langen KJ et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by 123 I-metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998; 41: 443-451.10.1007/s0012500509289562349
- 32. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol 2012; 8(7):405-41610.1038/nrendo.2012.2122371159
- 33. Spallone V, Ziegler D, Freeman R et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis and management. Diabetes Metab Res Rev 2011; 27: 639-65310.1002/dmrr.123921695768
- 34. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.10.1161/CIRCULATIONAHA.106.17929417192512
- 35. Pop-Busui R, Low PA, Waberski BH et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119: 2886-2893.10.1161/CIRCULATIONAHA.108.837369275700519470886
- 36. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 2:434-441.10.2337/dc09-1294280929820103559
- 37. Nathan DM, Genuth S, Lachin J et al. The effect of intensive treatment of diabetes on the development and progression of long-therm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.10.1056/NEJM1993093032914018366922
- 38. The Diabetes Control and Complications Trial Research Group.The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568.10.7326/0003-4819-122-8-199504150-000017887548
- 39. Martin CL, Albers J, Herman WH et al. Neuropathy among diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344.10.2337/diacare.29.02.06.dc05-1549262272016443884
- 40. Pop-Busui R, Herman WH, Feldman EL et al. DDCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010; 10: 276-282.10.1007/s11892-010-0120-8360867220464532
- 41. Witte DR, Tesfaye S, Chaturvedi N et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48: 164-171.10.1007/s00125-004-1617-y15619072
- 42. Brownlee M. Diabetic complications: pathobiology of hyperglycemic damage and potential impact on treatment. In: Thornalley PJ, Kempler P [Eds]. Complications of diabetes mellitus: pathophysiology and pathogenetically-based treatment options, Georg Thieme Verlag KG Stuttgart 2009: 1-8.
- 43. Hammes HP. Diabetic nerve, vascular and organ damage from the pathogenetic key to new therapeutic approaches. In: Rett K [Ed]. Better chances for nerves and vessels, Georg Thieme Verlag KG Stuttgart 2011: 9-19.
- 44. Pop Busui R. What do we know and what we do not know about cardiovascular autonomic neuropathy in diabetes. J Cardiovasc Trans Res 2012; 5: 463-478.10.1007/s12265-012-9367-6363456522644723
- 45. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.10.1136/bmj.321.7258.4052745410938048
- 46. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.10.1056/NEJMoa0806470
- 47. Jermendy G. Late effect of treatment for reducing cardiovascular risk-a hypothesis on cardiometabolic therapeutic memory. Med Hypotheses 2009; 73: 73-79.10.1016/j.mehy.2009.01.034
- 48. Ohkubo Y, Kishikawa H, Araki E, Miyata T et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabets Res Clin Pract 1995; 28:103-11710.1016/0168-8227(95)01064-K
- 49. Azad N, Emanuele NV, Abraira C et al. The effects of intensive glycemic control on neuropathy in the VA Cooperative Study on type II diabetes mellitus. J Diabetes Complications 1999; 13: 307-313.10.1016/S1056-8727(99)00062-8
- 50. Gaede P, Vedel P, Larsen GV et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.10.1056/NEJMoa02177812556541
- 51. Maser RE, Mitchell BD, Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895-1901.10.2337/diacare.26.6.189512766130
- 52. Ziegler D, Zentai CP, Perz S et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556-56110.2337/dc07-161518086873
- 53. Bolli GB, Fanelli CG, Porcellati F et al. Diabetic autonomic neuropathy. Response to hypoglycemia. In: Gries FA, Cameron NE, Low PA, Ziegler D [Eds]. Textbook of diabetic neuropathy, Georg Thieme Verlag, Stuttgart 2003:286-295.
- 54. Adler GK, Bonyhay I, Failing H et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009; 58: 360-366.10.2337/db08-1153262860919056608
- 55. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552-1561.10.1007/s00125-010-1752-620407743
- 56. Stephenson JM, Kempler P, Perin PC et al. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1372-1376.10.1007/s0012500505858933007
- 57. Meyer C, Grossman R, Mitrakou A et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21:1960-1966.10.2337/diacare.21.11.19609802751
- 58. Gerstein HC, Miller ME, Byintgton RP et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008; 358: 2545-2559.10.1056/NEJMoa0802743455139218539917
- 59. Gerstein HC, Riddle MC, Kendall DM et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 34-43.10.1016/j.amjcard.2007.03.00417599423
- 60. Calles-Escandon J, Lovato LC, Simons-Morton DG et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 721-727.10.2337/dc09-1471284501220103550
- 61. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32:187-192.10.2337/dc08-9026260681219092168
- 62. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystall ball for cardiovascular disease. Diabetes Care 2010; 33: 1688-1690.10.2337/dc10-0745289038220587730
- 63. Vinik AI. The conductor of the autonomic orchestra. Frontiers in Endocrinology 2012; ID 103389.10.3389/fendo.2012.00071338037622737143
- 64. Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610.10.1097/01.hjh.0000217838.49842.1e16531784
- 65. Kadoi Y. Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus. J Anesth 2010; 24: 739-747.10.1007/s00540-010-0987-120640453
- 66. Young LH, Wackers FJ, Chyun DA et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301:1547-1555.10.1001/jama.2009.476289533219366774
- 67. Maser RE, Mitchell BD, Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895-1901.10.2337/diacare.26.6.189512766130
- 68. Dinh W, Futh R, Lankisch M et al. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet Med 2011; 28: 311-318.
- 69. Brotman DJ, Bash LD, Qayyum R et al. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010; 21: 1560-1570.10.1681/ASN.2009111112301352420616169
- 70. Valensi P, Cosson E. It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes Metab 2010; 36: 91-96.10.1016/j.diabet.2010.01.00120189425